Fortrea (FTRE) and Its Rivals Financial Comparison

Fortrea (NASDAQ:FTREGet Free Report) is one of 46 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its peers? We will compare Fortrea to similar companies based on the strength of its dividends, earnings, analyst recommendations, risk, profitability, institutional ownership and valuation.


This table compares Fortrea and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Fortrea -4.11% 4.76% 1.87%
Fortrea Competitors -3,334.93% -1,311.64% -38.79%

Analyst Ratings

This is a summary of current recommendations for Fortrea and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fortrea 1 4 5 1 2.55
Fortrea Competitors 308 1200 2088 33 2.51

Fortrea currently has a consensus target price of $32.78, suggesting a potential upside of 31.74%. As a group, “Medical laboratories” companies have a potential upside of 25.62%. Given Fortrea’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Fortrea is more favorable than its peers.

Valuation & Earnings

This table compares Fortrea and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Fortrea $3.11 billion -$3.40 million -17.90
Fortrea Competitors $995.65 million -$125.17 million 4.49

Fortrea has higher revenue and earnings than its peers. Fortrea is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

47.5% of shares of all “Medical laboratories” companies are owned by institutional investors. 0.1% of Fortrea shares are owned by insiders. Comparatively, 18.8% of shares of all “Medical laboratories” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Fortrea beats its peers on 8 of the 12 factors compared.

Fortrea Company Profile

(Get Free Report)

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with's FREE daily email newsletter.